drugset / Trial / NCT00002203

A Study of Two Anti-HIV Drug Combinations

NCT00002203

Completed Glaxo Wellcome
Parallel-groupTreatment

Summary

The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI. This study also examines how well patients follow the dosing schedules for these drugs. Doctors believe that taking Combivir plus a PI may be as effective as taking 3TC plus ZDV plus a PI.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 150 mg
Subject Zidovudine Small molecule 200 mg
Subject Zidovudine Small molecule 300 mg